REGULATORY

MHLW Compiles New Clinical Assessment Guidelines on Neuropathic Pain Drugs

January 7, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) has compiled new “guidelines on the clinical assessment of treatments for neuropathic pain,” which among other things present standard methods for clinical trials of such drugs. The guidelines were drafted by a…

To read the full story

AMED Study Group to Draft Guidelines to Promote Expanded Indications for Neuropathic Pain Drugs
November 6, 2018

REGULATORY

Update: DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…